Phase 2 Completed N=78 Randomized Triple-blind Other

Beta-glucan and Immune Response to Influenza Vaccine

Healthy Aging

Source: ClinicalTrials.gov NCT05074303 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Mar 2025

Primary outcomePrimary: Antibody Titer — 127; 143; 241; 160 Titer

Summary

This trial in healthy adults will determine the effects of beta-glucan, a dietary fiber supplement isolated from baker's yeast, on immune response to the influenza vaccine.

Outcome Measures

Outcome	Result	p-value
PRIMARY Antibody Titer	127; 143; 241; 160	—
SECONDARY Inflammatory Cytokine Profile	2.3; 2.4; 8.2; 8.3; 3.3; 2.3	—
SECONDARY Incidence of Influenza and Covid-19	0; 0	—
SECONDARY Fever	1; 1	—
SECONDARY Cold and Flu Symptoms	0.92; 0.70	—

Eligibility Criteria

Inclusion Criteria

Adult volunteers ≥ 50 years of age.
Planning to be vaccinated for influenza
Have been immunized for COVID-19
Willing and able to provide written informed consent in English.
Willing and able to comply with all the study-related procedures, including attending to study visits for blood draw, taking the influenza vaccine, intake of the study supplement, and completing study questionnaires.

Exclusion Criteria

Demonstrate an inability to comply with the study-related procedures.
Have a history of a severe reaction or hypersensitivity following vaccination with influenza vaccine, vaccination with any other vaccine containing the same substances, or intake of the study product.
Have an immune system alteration because of an underlying illness (e.g., autoimmune disease) or immune-suppressing treatment (e.g., steroids (last 30 days); cytotoxic drugs, medical surgery, or radiation therapy during the 6 months, previous to enrollment).
Be concurrently participating in a clinical trial that, in the judgement of the investigator, would interfere with the evaluation of the study outcomes.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05074303). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.